CompletedNot Applicable

Prevalence of Cutaneous Enterococci at Femoral Insertion Site in Transcatheter Aortic Valve Implantation (TAVI)

France100 participantsStarted 2021-06-17

Plain-language summary

The general rules of antibiotic prophylaxis in surgery or interventional medicine include the choice of an antibiotic active on the bacteria most frequently encountered in surgical site infections. This antibiotic must cover, the bacteria present on the skin and recognized as responsible for surgical site infections. The aim of this study is to identify bacteria found in skin flora in the inguinal region of patients undergoing Transcatheter Aortic Valve Implantation (TAVI). Flora found will allow to evaluate the impact of skin preparation and antibiotic prophylaxis protocols as they are currently practiced.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient scheduled for aortic valve replacement by TAVI procedure with trans femoral approach * Patient with pre-TAVI assessment performed at Clinique Pasteur * Patient affiliated or beneficiary of a social security scheme * Patient accepting to participate and having given his no objection Exclusion Criteria: * TAVI procedure by non-trans femoral approach * Protected patients: Adults under guardianship or other legal protection; Pregnant or breastfeeding woman; Hospitalized without consent.

What they're measuring

Enterococci prevalence

Timeframe: At Day 0 at TAVI intervention time (preoperative)

Trial details

NCT IDNCT04909424

SponsorClinique Pasteur

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-02-21

View on ClinicalTrials.gov More Aortic Valve Disease trials